<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1928</article-id><article-id pub-id-type="doi">10.15789/2220-7619-EOT-1928</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Evaluation of the effects in the <italic>in vitro</italic> system of synthetic thymic hexapeptide on the expression levels of NF-κB, IFNα/βR and CD119 neutrophilic granulocytes in patients with chronic herpes viral co-infections</article-title><trans-title-group xml:lang="ru"><trans-title>Оценка влияния синтетического тимического гексапептида в системе <italic>in vitro</italic> на уровни экспрессии NF-κb, IFNα/βR и CD119 нейтрофильных гранулоцитов у пациентов с хроническими герпесвирусными коинфекциями</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nesterova</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Нестерова</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Department of Allergology and Immunology</p></bio><bio xml:lang="ru"><p>
</p><p>д.м.н., профессор, профессор кафедры аллергологии и иммунологии</p>
</bio><email>inesterova1@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khalturina</surname><given-names>E. O.</given-names></name><name xml:lang="ru"><surname>Халтурина</surname><given-names>Е. О.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Medicine), Associate Professor, Department of Microbiology, Virology and Immunology</p></bio><bio xml:lang="ru"><p>
</p><p>к.м.н., доцент, доцент кафедры микробиологии, вирусологии и иммунологии</p>
</bio><email>jane_k@inbox.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nelubin</surname><given-names>V. N.</given-names></name><name xml:lang="ru"><surname>Нелюбин</surname><given-names>В. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, MD (Medicine), Professor</p></bio><bio xml:lang="ru"><p>
</p><p>д.м.н., профессор</p>
</bio><email>vlnelyubin@mail.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khaidukov</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Хайдуков</surname><given-names>С. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, MD (Biology), Senior Researcher, Carbohydrate Laboratory</p></bio><bio xml:lang="ru"><p>
</p><p>д.б.н., старший научный сотрудник лаборатории углеводов</p>
</bio><email>hsv@mail.ibch.ru</email><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Chudilova</surname><given-names>G. A.</given-names></name><name xml:lang="ru"><surname>Чудилова</surname><given-names>Г. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, MD (Biology), Associate Professor, Department of Clinical Immunology, Allergology and Laboratory Diagnostics</p></bio><bio xml:lang="ru"><p>
</p><p>д.б.н., доцент кафедры клинической иммунологии, аллергологии и лабораторной диагностики факультета повышения квалификации и профессиональной переподготовки специалистов</p>
</bio><email>chudilova2015@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">The Peoples’ Friendship University of Russia</institution></aff><aff><institution xml:lang="ru">ФГАБОУ ВО Российский университет дружбы народов Министерства образования и науки России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Kuban State Medical University</institution></aff><aff><institution xml:lang="ru">ЦНИЛ ФГБОУ ВО Кубанский государственный медицинский университет Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО Первый МГМУ имени И.М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Moscow State University of Medicine and Dentistry</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry</institution></aff><aff><institution xml:lang="ru">ФНЦ ФГБУН Институт биоорганической химии им. акад. М.М. Шемякина и Ю.А. Овчинников</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2022-06-17" publication-format="electronic"><day>17</day><month>06</month><year>2022</year></pub-date><pub-date date-type="pub" iso-8601-date="2022-11-16" publication-format="electronic"><day>16</day><month>11</month><year>2022</year></pub-date><volume>12</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>850</fpage><lpage>858</lpage><history><date date-type="received" iso-8601-date="2022-04-16"><day>16</day><month>04</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-05-03"><day>03</day><month>05</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Nesterova I.V., Khalturina E.O., Nelubin V.N., Khaidukov S.V., Chudilova G.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Нестерова И.В., Халтурина Е.О., Нелюбин В.Н., Хайдуков С.В., Чудилова Г.А.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Nesterova I.V., Khalturina E.O., Nelubin V.N., Khaidukov S.V., Chudilova G.A.</copyright-holder><copyright-holder xml:lang="ru">Нестерова И.В., Халтурина Е.О., Нелюбин В.Н., Хайдуков С.В., Чудилова Г.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/1928">https://iimmun.ru/iimm/article/view/1928</self-uri><abstract xml:lang="en"><p><italic>Background.</italic> Strategies used by herpes viruses with human cells are complex and multifaceted. On one hand, inborn defects in antiviral immune defense have been unveiled, which also affect interferon (IFN) system underlying development of chronic recalcitrant relapsing viral infections such as remittent respiratory viral infections, herpesvirus infections, and papillomavirus infections. On the other hand, numerous viruses are able to damage both immune system and IFN network. During inborn and acquired defects in IFN network, inborn or induced mutation in gene products involved in signaling cascades aimed at upregulating gene expression responsible for IFN production are observed. One of the strategies used by diverse viruses is altering some signaling pathways resulting in activated transcription factors including nuclear factor NF-kB. However, antiviral mechanisms executed by neutrophilic granulocytes (NGs), particularly affecting NF-kB expression have not been elucidated. Aim of the study: to study <italic>in vitro</italic> features of NF-kB expression and number of neutrophilic granulocytes (NG) expressing membrane IFNα/βR and IFNγR in patients with atypical chronic active herpes virus infections (AChA-HVI), followed by assessing an effect of arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine — hexapeptide (HP), a synthetic analogue of the active center of the thymopoietin (active substance of drug “Imunofan”, Russia), on the expression of NG NF-kB and IFNα/βR and IFNγR. <italic>Materials and methods.</italic> We observed 25 patients of both sexes aged 23 to 64 years with AChA-HVI, manifested by chronic fatigue syndrome and cognitive disorders. Study design: stage 1 — clinical, ELISA, PCR methods, FC was used. Stage 2 — the <italic>in vitro</italic> experiment: 32 blood samples from 8 healthy adults and 375 blood samples from 25 patients with AChA-HVI were analyzed: % NG expressing NF-kB, IFNα/βR, IFNγR and the relevant MFI levels by using FC before and after incubation with HP. <italic>Results.</italic> Our study demonstrated low level (MFI) of NF-kB expression in 100% NG associated with decreased % of NG expressing IFNα/βR and IFNγR in all patients with AChA-HVI and low serum level for IFNα and IFNγ in comparison with healthy individuals. In the <italic>in vitro</italic> experiment there was shown that 100% of NG expressed NF-kB after exposure to HP. However, only 48% patients (SG 2) restored NF-kB expression level (MFI) to normal range and 52% of cases (SG 1) had no response. HP increased % of NG expressing IFNα/βR in SG 2 and increased % of NG expressing IFNγR in SG 1. <italic>Conclusions.</italic> It was shown, that influence of HP “<italic>in vitro</italic>” has ambiguous effects on the expression of NF-kB, % of NG expressing IFNα/βR and IFNγR in patients with AChA-HVI. We assume that different NF-kB response to HP is associated with inborn or secondary NF-kB deficiency.</p></abstract><trans-abstract xml:lang="ru"><p>Стратегии взаимодействие герпесвирусов с клетками организма человека весьма сложны и многогранны. С одной стороны, существуют врожденные дефекты противовирусной иммунной защиты, в том числе и системы интерферонов, на фоне которых развиваются хронические упорно рецидивирующие вирусные инфекции, такие как повторные респираторные вирусные, герпесвирусные, папилломавирусные инфекции. С другой стороны, многие вирусы сами способны повреждать как иммунную систему, так и систему интерферонов. При врожденных и приобретенные дефектах системы интерферонов наблюдается врожденная или индуцированная мутация генов молекул, участвующих в сигналлинге, направленном на повышение экспрессии генов, ответственных за синтез IFN. Одной из стратегий вирусов является нарушение ряда клеточных сигнальных путей — факторов транскрипции, в том числе ядерного фактора NF-kB. В настоящее время описана противовирусная активность НГ. При этом механизмы противовирусной защиты нейтрофильных гранулоцитов (НГ) и в частности особенности экспрессии NF-kB в доступной нам литературе не освещены. Цель исследования: изучить особенности экспрессии ядерного фактора NF-kB, мембранных рецепторов к IFNα и IFNγ на НГ у пациентов, страдающих атипичными хроническими активными герпесвирусными инфекциями (АХА-ГВИ), с последующей оценкой в эксперименте <italic>in</italic> <italic>vitro</italic> эффектов влияния на них синтетического аналога активного центра гормона тимопоэтина аргинил-альфа-аспартил-лизил-валил-тирозил-аргинин (гексапептид (ГП), Иммунофан, Россия). <italic>Материалы и методы.</italic> Под нашим наблюдением находилось 25 пациентов обоих полов в возрасте от 23 до 64 лет, страдающих АХА-ГВИ, манифестирующими синдромом хронической усталости и различными когнитивными расстройствами. Дизайн исследования: этап 1 включал комплекс традиционных методов (сбор анамнеза, методы физикального обследования, ОАК и пр.), дополнительно для детекции герпес- вирусных инфекций использовались методы серодиагностики (определение IgM VCA EBV, IgG VCA EBV, IgM CMV, IgG CMV IgM HSV1/2, IgG HSV1/2 методом ИФА). Для обнаружения генома вирусов в биоматериалах (кровь, слюна, моча, соскоб с миндалин и задней стенки глотки) был использован метод ПЦР-РВ. Этап 2 — эксперимент <italic>in</italic> <italic>vitro</italic>: изучено 32 образца крови от 8 условно здоровых человек и 375 образцов крови от 25 пациентов с АХА-ГВИ: определен процент НГ, экспрессирующих NF-kB, IFNα/βR, IFNγR и уровни их MFI с помощью проточной цитофлюориметрии до и после инкубации с ГП (гексапептидом). <italic>Результаты.</italic> В результате проведенного исследования у пациентов, страдающих АХА-ГВИ, был выявлен низкий уровень экспрессии (MFI) NF-kB у 100% НГ, который сочетался со сниженным процентом НГ, экспрессирующих IFNα/βR и IFNγR, и низким уровнем сывороточных IFNα и IFNγ по сравнению со здоровыми людьми. В эксперименте <italic>in</italic> <italic>vitro</italic> ГП оказывает неоднозначные вариативные эффекты влияния на экспрессию ядерного фактора NF-kB и мембранных рецепторов IFNα/β и IFNγ НГ пациентов, страдающих АХА-ГВИ. Было показано, что 100% НГ экспрессировали NF-kB после воздействия ГП. Но только 48% пациентов (ГИ2) восстановили уровень экспрессии NF-kB (MFI) до нормального значения, а в 52% случаев (ГИ1) динамики не выявлено. В то же время ГП увеличил процент НГ, экспрессирующих IFNα/βR в ГИ2 и увеличил процент НГ, экспрессирующих IFNγ в ГИ 1. <italic>Заключение. </italic>Было показано, что ГП в эксперименте <italic>in</italic> <italic>vitro</italic> оказывает неоднозначное влияние на экспрессию NF-kB, процент НГ, экспрессирующих IFNα/β и IFNγR у пациентов с АХА-ГВИ. Мы предполагаем, что различный ответ на влияние ГП связан с врожденным или вторичным дефицитом NF-kB.</p></trans-abstract><kwd-group xml:lang="en"><kwd>herpesvirus infections</kwd><kwd>interferon system</kwd><kwd>nuclear factor NF-kB</kwd><kwd>neutrophilic granulocytes</kwd><kwd>transcription factors</kwd><kwd>hexapeptide</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>герпесвирусные инфекции</kwd><kwd>система интерферона</kwd><kwd>ядерный фактор NF-kB</kwd><kwd>нейтрофильные гранулоциты</kwd><kwd>факторы транскрипции</kwd><kwd>гексапептид</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Amici C., Belardo G., Rossi A., Santoro M.G. Activation of I kappa b kinase by herpes simplex virus type 1. A novel target for anti-herpetic therapy. J. Biol. Chem., 2001, vol. 276, no. 31, pp. 28759–28766.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Caselli E., Fiorentini S., Amici C., Di Luca D., Caruso A., Santoro M.G. Human herpesvirus 8 acute infection of endothelial cells induces monocyte chemoattractant protein 1-dependent capillary-like structure formation: role of the IKK/NF-kB pathway. Blood, 2007, vol. 109, no. 7, pp. 2718–2726. doi: 10.1182/blood-2006-03-012500</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Charostad J., Nakhaie M., Dehghani A., Faghihloo E. The interplay between EBV and KSHV viral products and NF-kB pathway in oncogenesis. Infect. Agents Cancer, 2020, vol. 15: 62. doi: 10.1186/s13027-020-00317-4</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Chew T., Taylor K.E., Mossman K.L. Innate and adaptive immune responses to herpes simplex virus. Viruses, 2009, vol. 1, pp. 979–1002. doi: 10.3390/v1030979</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>De Jesus A.A., Hou Y., Brooks S. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J. Clin. Invest., 2020, vol. 130, no. 4, pp. 1669–1682. doi: 10.1172/JCI129301</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>De Oliveira D.E., Ballon G., Cesarman E. NF-kB signaling modulation by EBV and KSHV. Trends Microbiol., 2010, vol. 18, no. 6, pp. 248–257.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Dell’Oste V., Gatti D., Giorgio A.G., Gariglio M., Landolfo S., De Andrea M. The interferon-inducible DNA-sensor protein IFI16: a key player in the antiviral response. New Microbiol., 2015, vol. 38, no. 1, pp. 5–20.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Ehrlich E.S., Chmura J.C., Smith J.C., Kalu N.N., Hayward G.S. KSHV RTA abolishes NF-kB responsive gene expression during lytic reactivation by targeting vFLIP for degradation via the proteasome. PLoS One, 2014, vol. 9, no. 3: e91359. doi: 10.1371/journal.pone.0091359</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Gianni T., Leoni V., Campadelli-Fiume G. Type I interferon and NF-kappaB activation elicited by herpes simplex virus gH/gL via alphavbeta3 integrin in epithelial and neuronal cell lines. J. Virol., 2013, vol. 87, no. 24, pp. 13911–13916.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Hatada E.N., Krappmann D., Scheidereit C. NF-kappaB and the innate immune response. Curr. Opin. Immunol., 2000, vol. 12, pp. 52–58. doi: 10.1016/S0952-7915(99)00050-3</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hiscott J. Convergence of the NF-kappaB and IRF pathways in the regulation of the innate antiviral response. Cytokine Growth Factor Rev., 2007, vol. 18, pp. 483–490.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Jiang J., Zhao M., Chang C., Wu H., Lu Q. Type I interferons in the pathogenesis and treatment of autoimmune diseases. Clin. Rev. Allergy Immunol., 2020, vol. 59, no. 2, pp. 248–272. doi: 10.1007/s12016-020-08798-2</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kalamvoki M., Roizman B. HSV-1 degrades, stabilizes, requires, or is stung by STING depending on ICP0, the US3 protein kinase, and cell derivation. Proc. Natl. Acad. Sci. USA, 2014, vol. 111, pp. E611–E617. doi: 10.1073/pnas.1323414111</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., Ishii K.J., Takeuchi O., Akira S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol., 2005, vol. 6, pp. 981–988. doi: 10.1038/ni1243</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Kim J.C., Lee S.Y., Kim S.Y., Kim J.K., Kim H.J., Lee H.M., Choi M.S., Min J.S., Kim M.J., Choi H.S., Ahn J.K. HSV-1 ICP27 suppresses NF-kappaB activity by stabilizing IkappaBalpha. FEBS Lett., 2008, vol. 582, no. 16, pp. 2371–2376. doi: 10.1016/ j.febslet.2008.05.044</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Le Negrate G. Viral interference with innate immunity by preventing NF-kappaB activity. Cell Microbiol., 2012, vol. 14, no. 2, pp. 168–181. doi: 10.1111/j.1462-5822.2011.01720.x</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lepelley A., Martin-Niclós M.J., Le Bihan M., Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling. J. Exp. Med., 2020, vol. 217, no. 11: e20200600. doi: 10.1084/jem.20200600</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Low-Calle A.M., Prada-Arismendy J., Castellanos J.E. Study of interferon-beta antiviral activity against Herpes simplex virus type 1 in neuron-enriched trigeminal ganglia cultures. Virus Res., 2014, vol. 180, pp. 49–58. doi: 10.1016/j.virusres.2013.12.022</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Ma F., Li B., Liu S.Y., Iyer S.S., Yu Y., Wu A., Cheng G. Positive feedback regulation of type I IFN production by the IFN-inducible DNA sensor cGAS. J. Immunol., 2015, vol. 194, pp. 1545–1554. doi: 10.4049/jimmunol.1402066</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Marino-Merlo F., Papaianni E., Frezza C., Pedatella S., De Nisco M., Macchi B., Grelli S., Mastino A. NF-kB-dependent production of ROS and restriction of HSV-1 infection in U937 monocytic cells. Viruses, 2019, vol. 11, no. 5: 428. doi: 10.3390/v11050428</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Michalska A., Blaszczyk K., Wesoly J., Bluyssen A positive feedback amplifier circuit that regulates interferon (IFN)-stimulated gene expression and controls type I and type II IFN responses. Front. Immunol., 2018, vol. 9: 1135. doi: 10.3389/fimmu.2018.01135</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>O’Neill L.A., Bowie A.G. Sensing and signaling in antiviral innate immunity. Curr. Biol., 2010, vol. 20, pp. R328–R333. doi: 10.1016/j.cub.2010.01.044</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Okada S., Asano T., Moriya K., Boisson-Dupuis S. Human STAT1 gain-of-function heterozygous mutations: chronic mucocutaneous candidiasis and type I interferonopathy. J. Clin. Immunol., 2020, vol. 40, no. 8, pp. 1065–1081. doi: 10.1007/s10875-020-00847-x</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Poma P. NF-kB and disease. Int. J. Mol. Sci., 2020, vol. 21, no. 23: 9181. doi: 10.3390/ijms21239181</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Roizman B., Whitley R.J. An inquiry into the molecular basis of HSV latency and reactivation. Annu. Rev. Microbiol., 2013, vol. 67, pp. 355–374. doi: 10.1146/annurev-micro-092412-155654</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Santoro M.G., Rossi A., Amici C. NF-kappaB and virus infection: who controls whom. EMBO J., 2003, vol. 22, pp. 2552–2560.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Sen R., Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 1986, vol. 46, no. 5, pp. 705–716.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Sun L., Wu J., Du F., Chen X., Chen Z.J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science, 2013, vol. 339, pp. 786–791. doi: 10.1126/science.1232458</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Swiecki M., Omattage N.S., Brett T.J. BST-2/tetherin: structural biology, viral antagonism, and immunobiology of a potent host antiviral factor. Mol. Immunol., 2013, vol. 54, pp. 132–139. doi: 10.1016/j.molimm.2012.11.008</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Unterholzner L. The interferon response to intracellular DNA: why so many receptors? Immunobiology, 2013, vol. 218, pp. 1312–1321. doi: 10.1016/j.imbio.2013.07.007</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Vahed H., Agrawal A., Srivastava R., Prakash S., Coulon P.A., Roy S., BenMohamed L. Unique type I interferon, expansion/survival cytokines, and JAK/STAT gene signatures of multifunctional herpes simplex virus-specific effector memory CD8+ TEM cells are associated with asymptomatic herpes in humans. J. Virol., 2019, vol. 93, no. 4: e01882-18. doi: 10.1128/JVI.01882-18</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Valentine R., Dawson C.W., Hu C., Shah K.M., Owen T.J., Date K.L., Maia S.P., Shao J., Arrand J.R., Young L.S., O’Neil J.D. Epstein–Barr virus-encoded EBNA1 inhibits the canonical NF-kB pathway in carcinoma cells by inhibiting IKK phosphorylation. Mol. Cancer., 2010, vol. 9, no. 1: 1. doi: 10.1186/1476-4598-9-1</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Van Lint A.L., Murawski M.R., Goodbody R.E., Severa M., Fitzgerald K.A., Finberg R.W., Knipe D.M., Kurt-Jones E.A. Herpes simplex virus immediate-early ICP0 protein inhibits Toll-like receptor 2-dependent inflammatory responses and NF-kappaB signaling. J. Virol., 2010, vol. 84, pp. 10802–10811. doi: 10.1128/JVI.00063-10</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Wang K., Ni L., Wang S., Zheng C. Herpes simplex virus 1 protein kinase US3 hyperphosphorylates p65/RelA and dampens NF-kappaB activation. J. Virol., 2014, vol. 88, pp. 7941–7951. doi: 10.1128/JVI.03394-13</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Wei H., Prabhu L., Hartley A.-V., Martin M., Sun E., Jiang G., Liu Y., Lu T. Methylation of NF-kB and its role in gene regulation. In: Gene expression and regulation in mammalian cells. Transcription from general aspects. Ed. by F. Uchiumi. Ch. 14. 2018, pp. 291–306. doi: 10.5772/intechopen.72552</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Wu D.X., Fu X.Y., Gong G.Z., Sun K.W., Gong H.Y., Novel HBV mutations and their value in predicting efficacy of conventional interferon. Hepatobiliary Pancreat Dis. Int., 2017, vol. 16, no. 2, pp. 189–196. doi: 10.1016/s1499-3872(16)60184-4</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Xing J., Ni L., Wang S., Wang K., Lin R., Zheng C. Herpes simplex virus 1-encoded tegument protein VP16 abrogates the production of beta interferon (IFN) by inhibiting NF-kappaB activation and blocking IFN regulatory factor 3 to recruit its coactivator CBP. J. Virol., 2013, vol. 87, pp. 9788–9801. doi: 10.1128/JVI.01440-13</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Yamashiro L.H., Wilson S.C., Morrison H.M. Interferon-independent STING signaling promotes resistance to HSV-1 in vivo. Nat. Commun., 2020, vol. 11, no. 1: 3382. doi: 10.1038/s41467-020-17156-x</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Zhang J., Wang S., Wang K., Zheng C. Herpes simplex virus 1 DNA polymerase processivity factor UL42 inhibits TNF-alpha-induced NF-kappaB activation by interacting with p65/RelA and p50/NF-kappaB1. Med. Microbiol. Immunol., 2013, vol. 202, pp. 313–325.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Zhang Q., Lenardo M.J., Baltimore D. 30 years of NF-kB: a blossoming of relevance to human pathobiology. Cell, 2017, vol. 168, no. 1–2, pp. 37–57. doi: 10.1016/j.cell.2016.12.012</mixed-citation></ref></ref-list></back></article>
